(Q58211591)

11

object named as

Chris Twelves

0 references

author name string

Jiri Horak

1

0 references

Jeff White

2

0 references

Mark Verrill

4

0 references

James Carmichael

5

0 references

Alison Holt

6

0 references

Mireille Cantarini

7

0 references

Merran Macpherson

8

0 references

Alan Swaisland

9

0 references

Helen Swaisland

Cancer Chemotherapy and Pharmacology

10

0 references

publication date

13 April 2011

0 references

published in

0 references

volume

68

0 references

issue

6

0 references

page(s)

1485-1495

0 references

cites work

Pharmacokinetics of vinorelbine in patients with liver metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Clinical pharmacokinetics of docetaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Cytochrome P450-dependent metabolism of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Single-dose clinical pharmacokinetic studies of gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1611-2